Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in May and June 2017.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.

In its late-stage licensing deal with GW Pharmaceuticals for Sativex, Bayer accepted UK-only rights, and will share the product's value equally with GW. This unusual agreement largely reflects the particular nature of the product. But it also shows that, at least in some situations, biotechs can still partner out their jewels without giving away too much value.

Summarizing the month in European dealmaking.